News
Sinergia will open its doors to Bellvitge health research and innovation
On the morning of Saturday, October 21, the 5th edition of Sinergia will bring the science of the Bellvitge Campus closer to citizens.
Researchers at CNIO and IDIBELL shed light on the role in lactation of a protein also crucial in breast cancer
When the RANK protein was suppressed in luminal cells of the breast tissue in female mice, they did not produce milk in their first pregnancy.
The IDIBELL’s spin-off ADmit therapeutics closes a €5.4 million funding round
ADmit Therapeutics is a biotechnology company founded at the end of 2017 as a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL). The company is focused on the development and commercialization of a new early detection technology for Alzheimer’s disease (AD) and has successfully closed a €5.4 million equity round.
Research led in Bellvitge will allow progress in the fight against bacteremia
The study has been published in the journal Nature Medicine, one of the most prestigious in Medicine, and represents a step forward to address an important health challenge worldwide, with high rates of therapeutic failure and mortality.
Sleep deprivation or working night shifts do not seem to be risk factors for endometrial cancer
A study by IDIBELL and ICO in 7,202 women with endometrial cancer and more than 22,000 control women found no relationship between lack of sleep or working night shifts with the development of this cancer.
Molecular tests allow more effective detection of endometrial cancer and avoid unnecessary hysterectomies in women with postmenopausal bleeding
The study performs an evaluation to determine the cost-effectiveness and profitability of two strategies for the early detection of endometrial cancer in women with postmenopausal bleeding.
One in three men worldwide are infected with genital human papillomavirus
1 in 3 men over the age of 15 are infected with at least one genital human papillomavirus (HPV) type, and 1 in 5 are infected with one or more of what are known as high risk, or oncogenic, HPV types
A new clinical algorithm increases the diagnosis rate of rare diseases
A research team led by Aurora Pujol and Dr. Carlos Casasnovas developed an innovative computational algorithm called ClinPrior. This algorithm demonstrated its ability to improve the diagnosis rate in patients with rare diseases of genetic origin.
Study shows the health risk of smoking in the car
This work, in which IDIBELL and the Catalan Institute of Oncology (ICO) participated, has analyzed the concentrations of nicotine in the air, as well as, cotinine and nitrosamines, specifically of tobacco dust in vehicles.